Skip to main content

Table 2 Hematological toxicities ( n = 359 )

From: Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

Low Dose (n = 60)

Total

Grade 1

Grade 2

Grade 3

Grade 4

Leukopenia

13 (21.7%)

5 (8.3%)

6 (10%)

2 (3.3%)

0 (0%)

Anemia

33 (55.0%)

24 (40%)

9 (15%)

0 (0%)

0 (0%)

Thrombocytopenia

13 (21.7%)

8 (13.3%)

3 (5.0%)

2 (3.3%)

0 (0%)

Intermediate Dose ( n = 77 )

     

Leukopenia

18 (23.4%)

9 (11.7%)

6 (7.8%)

3 (3.9%)

0 (0%)

Anemia

43 (55.8%)

35 (45.5%)

8 (10.4%)

0 (0%)

0 (0%)

Thrombocytopenia

23 (29.9%)

20 (26.0%)

2 (2.6%)

1 (1.3%)

0 (0%)

High Dose ( n = 222 )

     

Leukopenia

77 (34.7%)

31 (14.0%)

31 (14.0%)

13 (5.9%)

2 (0.9%)

Anemia

145 (65.3%)

117 (52.7%)

22 (9.9%)

5 (2.3%)

0 (0%)

Thrombocytopenia

92 (41.4%)

68 (30.6%)

11 (5.0%)

6 (2.7%)

7 (3.2%)

  1. All toxicities are scored according to the NCI criteria.